Ipsen wins positive EU panel view on drug Increlex

Fri May 25, 2007 6:21am EDT

[-] Text [+]

PARIS, May 25 (Reuters) - French drugmaker Ipsen (IPN.PA: Quote, Profile, Research, Stock Buzz) said on Friday it had won a positive opinion from the European Union's health expert panel for Increlex, which treats growth failure in children and adolescents.

If the drug wins the approval of the European Union health authority, the European Medicines Agency (EMEA), it will be marketed in the region with the help of Tercica (TRCA.O: Quote, Profile, Research, Stock Buzz).

Ipsen had filed Increlex for EU marketing authorisation in December 2005.

Increlex aims to treat growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency and in children with growth hormone gene deletion who have developed neutralising antibodies to growth hormone.

((Reporting by Caroline Jacobs, paris.equities@news.reuters.com; Reuters Messaging: caroline.jacobs.reuters.com@reuters.net; +33 1 49 49 53 43)) Keywords: IPSEN INCRELEX/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nPAC008201

Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.

Have a correction to this article? Email the editors